Prostate Cancer Radioligand Therapy Pipeline

Developing StoryLast updated JUN 4
SUMMARY

Novartis's Pluvicto received an expanded FDA indication on June 4, 2026, for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed on androgen receptor pathway inhibitors and are candidates for delayed chemotherapy. As of June 4, 2026, emerging research suggests prior vaccination for prostate cancer-specific antigens may double the rate of two-year overall survival in mCRPC patients treated with 177Lu-PSMA-617. The PSMAfore trial results, published in The Lancet, demonstrate that ¹⁷⁷Lu-PSMA-617 significantly prolonged progression-free survival in taxane-naive mCRPC patients, with Novartis also presenting updated data at ASCO 2026 showing Pluvicto more than doubled median radiographic progression-free survival. Regulatory submissions for Pluvicto are pending in the US, China, and Japan, with decisions anticipated in the second half of 2026, while the company withdrew its EU label expansion application in March 2026. Other developments include positive Phase 3 data for Telix Pharmaceuticals' TLX591-Tx, promising Phase 2 data for Convergent Therapeutics' CONV01-α, and the establishment of a recommended Phase 2 dose for 225Ac-PSMA-617 from the AcTION trial.

Timeline

Want updates on this thread?

Track this story

June 2026 — 8 developments

  1. Novartis's Pluvicto has received an expanded FDA indication for patients with PSMA-positive metastat…

    Novartis's Pluvicto has received an expanded FDA indication for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on androgen receptor pathway inhibitors and are candidates for delayed chemotherapy. Emerging research presented at SNMMI suggests prior vaccination for prostate cancer-specific antigens may double the rate of two-year overall survival in mCRPC patients treated with 177Lu-PSMA-617.

  2. Novartis has filed for regulatory submissions for Pluvicto in the US, China, and Japan, with decisions anticipated in the second half of 2026.

    Novartis has filed for regulatory submissions for Pluvicto in the US, China, and Japan, with decisions anticipated in the second half of 2026. The company also withdrew its EU label expansion application for Pluvicto in March 2026. Meanwhile, Tunisia began national production of 18F-PSMA in March 2026, and Actinium Pharmaceuticals presented new preclinical data for ATNM-400.

  3. The PSMAfore trial results, published in The Lancet, demonstrate that ¹⁷⁷Lu-PSMA-617 significantly p…

    The PSMAfore trial results, published in The Lancet, demonstrate that ¹⁷⁷Lu-PSMA-617 significantly prolonged progression-free survival in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, a novel theranostic approach targeting the rearranged during transfection (RET) biomarker could help treat PSMA-negative neuroendocrine prostate cancer, offering a potential new avenue for patients with this subtype.

  4. Novartis presented updated data from the PSMAfore trial at ASCO 2026, showing Pluvicto (lutetium PSM…

    Novartis presented updated data from the PSMAfore trial at ASCO 2026, showing Pluvicto (lutetium PSMA-617) more than doubled median radiographic progression-free survival (rPFS) compared to a change in androgen receptor pathway inhibitor (ARPI) in men with metastatic castration-resistant prostate cancer (mCRPC) who progressed on ARPI and were chemotherapy-naïve.

  5. The Phase 1 AcTION trial has established a recommended Phase 2 dose (RP2D) for 225Ac-PSMA-617, an al…

    The Phase 1 AcTION trial has established a recommended Phase 2 dose (RP2D) for 225Ac-PSMA-617, an alpha-emitting radioligand therapy, demonstrating a manageable safety profile and promising responses in metastatic castration-resistant prostate cancer patients. New subgroup analyses from the Phase 3 PSMAddition trial indicate that adding Pluvicto to standard therapies provides a survival benefit. A novel theranostic approach targeting RET for neuroendocrine prostate cancer was also introduced, expanding therapeutic options for patients with limited imaging visualization.

  6. Telix Pharmaceuticals presented positive Phase 3 ProstACT Global Study data for its PSMA-targeted lu…

    Telix Pharmaceuticals presented positive Phase 3 ProstACT Global Study data for its PSMA-targeted lutetium radio antibody-drug conjugate, TLX591-Tx, at ASCO 2026, indicating an acceptable safety profile. Novartis also shared new data from the Phase III PSMAddition trial, showing Pluvicto significantly reduced the risk of PSA progression in metastatic hormone-sensitive prostate cancer.

  7. Convergent Therapeutics announced positive Phase 2 data for CONV01-α in metastatic castration-resistant prostate cancer patients.

    Convergent Therapeutics announced positive Phase 2 data for CONV01-α in metastatic castration-resistant prostate cancer patients. Novartis presented promising Phase 1 data for investigational actinium-based radioligand therapies, and the PSMAfore trial showed ¹⁷⁷Lu-PSMA-617 extended time before cancer progression. Separately, Novartis received a Complete Response Letter from the FDA regarding its supplemental New Drug Application for Pluvicto.

  8. SHINE Technologies secured EU market authorization for its radioisotope product Ilumira (non-carrier…

    SHINE Technologies secured EU market authorization for its radioisotope product Ilumira (non-carrier-added lutetium-177), broadening access to Lu-177 for targeted radioligand therapies. Convergent Therapeutics presented promising Phase 2 data for CONV01-α in metastatic castration-resistant prostate cancer patients. Curium is investing over €32 million in France to establish a European production line for 177Lu-PSMA-I&T.

May 2026 — 6 developments

  1. Novartis presented early data at ASCO 2026 showing their investigational actinium-based radioligand …

    Novartis presented early data at ASCO 2026 showing their investigational actinium-based radioligand therapy, 225Ac-PSMA-617, demonstrated anti-tumor activity in prostate cancer patients, including those previously treated with Pluvicto. Separately, a new machine-learning approach presented at the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting could personalize PSMA therapy dosing by estimating radiation dose to tumors and healthy organs. Eden Radioisotopes has also filed an application to construct a new facility in New Mexico to increase the domestic supply of medical isotopes like lutetium-177.

  2. Tempus AI has launched the ArteraAI Prostate Test, an AI-powered tool that analyzes clinical data and biopsy images to estimate the risk of prostate cancer-specific mortality.

    Tempus AI has launched the ArteraAI Prostate Test, an AI-powered tool that analyzes clinical data and biopsy images to estimate the risk of prostate cancer-specific mortality. This development personalizes therapy intensity for patients with metastatic hormone-sensitive prostate cancer (mHSPC).

  3. Pluvicto sales reached $2 billion in 2025, marking a 43% year-over-year increase.

    Pluvicto sales reached $2 billion in 2025, marking a 43% year-over-year increase. Novartis is pursuing expanded use in metastatic hormone-sensitive prostate cancer (mHSPC) based on positive Phase III PSMAddition trial data, with decisions anticipated in the second half of 2026 for submissions in the U.S., China, and Japan.

  4. The U.S. Food and Drug Administration (FDA) has expanded the label for gallium Ga-68 gozetotide (Ill…

    The U.S. Food and Drug Administration (FDA) has expanded the label for gallium Ga-68 gozetotide (Illuccix) to include patient selection for PSMA-targeted radioligand therapy before taxane-based chemotherapy in men with mCRPC. Real-world studies also indicate Pluvicto achieved longer progression-free survival when initiated after one androgen receptor pathway inhibitor rather than multiple.

  5. Novartis has filed supplemental new drug applications in the US, China, and Japan for Pluvicto in me…

    Novartis has filed supplemental new drug applications in the US, China, and Japan for Pluvicto in metastatic hormone-sensitive prostate cancer (mHSPC), with decisions anticipated in the second half of 2026. New data from the Phase III PSMAddition trial showed a 58% lower risk of PSA progression when Pluvicto is combined with standard of care in PSMA-positive mHSPC patients.

  6. Telix Pharmaceuticals is developing next-generation PSMA-targeted therapies, including TLX597-Tx, with early dosimetry data suggesting low uptake in salivary glands and kidneys.

    Telix Pharmaceuticals is developing next-generation PSMA-targeted therapies, including TLX597-Tx, with early dosimetry data suggesting low uptake in salivary glands and kidneys. Research also highlights that a combination therapy of Pluvicto and stereotactic body radiotherapy (SBRT) shows potential in delaying progression in recurrent prostate cancer, and early SPECT/CT imaging after Pluvicto treatment may predict long-term survival in mCRPC patients.

April 2026 — 7 developments

  1. Novartis is expanding its infrastructure, including a new plant in California, to meet anticipated demand for Pluvicto, projecting over $5 billion in annual product revenues.

    Novartis is expanding its infrastructure, including a new plant in California, to meet anticipated demand for Pluvicto, projecting over $5 billion in annual product revenues. Recent research also indicates that PSMA therapy is effective in earlier prostate cancer stages, potentially delaying hormone therapy by an average of twenty months and doubling progression-free survival when used before other treatments.

  2. Novartis has withdrawn its European Medicines Agency (EMA) application for an expanded indication of…

    Novartis has withdrawn its European Medicines Agency (EMA) application for an expanded indication of Pluvicto for pre-chemotherapy treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). This decision follows feedback from the EMA's Committee for Medicinal Products for Human Use (CHMP) regarding concerns about the control arm of the PSMAfore study.

  3. Early data from a Phase 1 study of Actinium-225 FL-020, a PSMA-targeted alpha-emitting radioligand t…

    Early data from a Phase 1 study of Actinium-225 FL-020, a PSMA-targeted alpha-emitting radioligand therapy, shows promising safety and tolerability in patients with metastatic castration-resistant prostate cancer (mCRPC). Convergent Therapeutics will present Phase 2 data for its PSMA-targeted actinium-225 (Ac-225) radioantibody, CONV01-α, at the 2026 ASCO Annual Meeting.

  4. The Barbara Ann Karmanos Cancer Institute announced the expansion of access to radiopharmaceutical t…

    The Barbara Ann Karmanos Cancer Institute announced the expansion of access to radiopharmaceutical therapies, including Pluvicto, to additional Karmanos Cancer Network locations in Michigan. This expansion aims to provide more targeted treatment options for oncology patients with metastasized disease.

  6. Novartis is investigating Pluvicto for earlier stages of prostate cancer, including metastatic hormo…

    Novartis is investigating Pluvicto for earlier stages of prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC), showing significant improvement in radiographic progression-free survival. A Phase 1 trial for a new PSMA-targeted T-cell engager has also commenced for patients with mCRPC.

  7. A meta-analysis presented in February 2026 indicated that Pluvicto offers improved progression-free survival in advanced prostate cancer without increasing serious adverse events.

    A meta-analysis presented in February 2026 indicated that Pluvicto offers improved progression-free survival in advanced prostate cancer without increasing serious adverse events. Furthermore, a study published in March 2026 in The Lancet Oncology demonstrated that PSMA therapy can effectively postpone the need for more burdensome hormone therapy in patients with limited metastatic prostate cancer, delaying it by an average of twenty months.

March 2026 — 4 developments

  1. The FDA has expanded the approved indication for Pluvicto to include adults with PSMA-positive metas…

    The FDA has expanded the approved indication for Pluvicto to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy. Telix Pharmaceuticals is advancing its PSMA-targeted radiopharmaceutical, TLX-591-Tx, and plans to submit data to the FDA. Novartis is experiencing supply chain issues for its lutetium-177 radiopharmaceutical treatment but is working to expedite the approval of an additional manufacturing facility.

  2. The FDA has approved an expanded indication for Novartis' Pluvicto, allowing its use earlier in adva…

    The FDA has approved an expanded indication for Novartis' Pluvicto, allowing its use earlier in advanced prostate cancer treatment, specifically after ARPI therapy and before chemotherapy. This decision, based on the Phase 3 PSMAfore trial, potentially triples the number of eligible patients by demonstrating a 59% reduction in the risk of radiographic progression or death.

  3. A new PSMA-targeted radioligand therapy, when administered before stereotactic body radiotherapy, mo…

    A new PSMA-targeted radioligand therapy, when administered before stereotactic body radiotherapy, more than doubled progression-free survival in patients with recurrent prostate cancer, extending it from 7.4 months to 17.6 months. This combination therapy reduced the risk of cancer returning, the need for hormone therapy, or death by 63%. Patients also experienced a significant delay in starting hormone therapy, with a median of 24.3 months compared to 14.1 months in the control group.

  4. Bayer has announced promising results from its Phase I PAnTHa study of 225Ac-PSMA-Trillium, an inves…

    Bayer has announced promising results from its Phase I PAnTHa study of 225Ac-PSMA-Trillium, an investigational targeted alpha therapy for advanced metastatic castration-resistant prostate cancer. The study demonstrated significant antitumor activity, with a 62% PSA response rate and a 50% overall response rate across all doses, and notably, an 83% PSA50 response rate and 71% overall response rate at the 125 kBq/kg dose.

February 2026 — 14 developments

  1. New findings from the PSMAddition study, presented at the 2026 Genitourinary Cancers Symposium, indi…

    New findings from the PSMAddition study, presented at the 2026 Genitourinary Cancers Symposium, indicate that Pluvicto (lutetium Lu 177 vipivotide tetraxetan) combined with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) maintained quality-of-life outcomes in patients with metastatic hormone-sensitive prostate cancer. This was compared to ADT plus an ARPI alone, with a median follow-up of 23.6 months.

  2. Bayer presented data from its Phase I PAnTHa study of the investigational targeted alpha therapy 225…

    Bayer presented data from its Phase I PAnTHa study of the investigational targeted alpha therapy 225Ac-PSMA-Trillium for advanced metastatic castration-resistant prostate cancer at the 2026 ASCO Genitourinary Cancers Symposium. The results support advancing this therapy to the next phase of development, positioning it as a strategic pillar in Bayer's precision oncology efforts for mCRPC patients.

  3. Curium presented pharmacokinetics and dosimetry data for its investigational lutetium-177 zadavotide guraxetan at the ASCO GU 2026 symposium.

    Curium presented pharmacokinetics and dosimetry data for its investigational lutetium-177 zadavotide guraxetan at the ASCO GU 2026 symposium. The data from a substudy of the Phase 3 ECLIPSE trial showed projected mean cumulative renal doses remained low for PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer patients.

  4. Novartis announced the construction of a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, its fifth RLT site in the U.

    Novartis announced the construction of a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, its fifth RLT site in the U.S., expected to be operational by 2028. New real-world data presented at the ASCO Genitourinary Cancers Symposium reinforce the earlier use of Pluvicto before chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), showing a median progression-free survival (PFS) of 13.5 months in chemo-naïve patients. Additionally, researchers identified genetic mutations (TP53, PTEN, RB1) linked to inferior overall survival in Pluvicto-treated patients.

  5. Novartis announced its intention to build a new radioligand therapy (RLT) manufacturing site in Denton, Texas, its fifth RLT facility in the U.

    Novartis announced its intention to build a new radioligand therapy (RLT) manufacturing site in Denton, Texas, its fifth RLT facility in the U.S. The new 46,000-square-foot facility, expected to be operational by 2028, is part of Novartis's $23 billion investment in the U.S. and aims to expand their capacity for producing next-generation treatments.

  6. New real-world data presented at the ASCO Genitourinary Cancers Symposium reinforce the earlier use …

    New real-world data presented at the ASCO Genitourinary Cancers Symposium reinforce the earlier use of Pluvicto before chemotherapy in metastatic castration-resistant prostate cancer (mCRPC), demonstrating a median progression-free survival (PFS) of 13.5 months in chemo-naïve patients. Separately, the Prostate Cancer Foundation announced a $10 million gift to launch the TACTICAL Award, which will focus on understanding and overcoming resistance to 177Lu-PSMA-617 (Pluvicto®).

  7. Researchers have identified that certain genetic mutations, including TP53, PTEN, and RB1, are linke…

    Researchers have identified that certain genetic mutations, including TP53, PTEN, and RB1, are linked to inferior overall survival in patients treated with Pluvicto (lutetium-177 PSMA-617) for advanced prostate cancer. A study involving 72 patients found these mutations may serve as prognostic biomarkers for treatment outcomes.

  8. A meta-analysis of over 2500 patients presented at the Multidisciplinary Radiopharmaceutical Therapy…

    A meta-analysis of over 2500 patients presented at the Multidisciplinary Radiopharmaceutical Therapy Symposium showed that Pluvicto (Lu-177 PSMA-617) significantly improved progression-free survival (PFS) in advanced prostate cancer patients compared to standard treatment. The study found no increase in adverse events for patients receiving Pluvicto. Pooled results presented at the American Society for Radiation Oncology's symposium also indicated Pluvicto consistently prolongs PFS.

  9. Eli Lilly has ceased development of three therapies, including a radioligand therapy (AC-225-PSMA-62) that was in a Phase I/II trial for prostate cancer.

    Eli Lilly has ceased development of three therapies, including a radioligand therapy (AC-225-PSMA-62) that was in a Phase I/II trial for prostate cancer. The decision to terminate the development was based on efficacy concerns, with safety not being a factor.

  10. Curium Group, in collaboration with PeptiDream Inc.

    Curium Group, in collaboration with PeptiDream Inc. and PDRadiopharma Inc., has initiated a registrational clinical trial for 177Lu-PSMA-I&T in Japan. The first patient has been dosed in this Phase 2 trial, which will evaluate the efficacy of the treatment for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

  11. Novartis announced that Pluvicto received MHRA approval in the UK on February 3, 2026, for a new indication.

    Novartis announced that Pluvicto received MHRA approval in the UK on February 3, 2026, for a new indication. This expanded approval allows Pluvicto to be administered to eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) earlier in their treatment pathway, specifically after progression on or after androgen receptor pathway inhibitor (ARPI) therapy and when delaying taxane-based chemotherapy is considered appropriate.

  12. The American Society of Clinical Oncology (ASCO) has released its first living guidelines for prosta…

    The American Society of Clinical Oncology (ASCO) has released its first living guidelines for prostate cancer, which now allow for Pluvicto to be used before chemotherapy in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Novartis is also pursuing an expanded label for Pluvicto to include patients in the pre-taxane chemotherapy setting.

  14. Kai Tsao of Northwell Health Cancer Institute is scheduled to participate in a debate discussing the optimal timing for Lutetium-177 (Pluvicto) therapy in advanced prostate cancer.

    Kai Tsao of Northwell Health Cancer Institute is scheduled to participate in a debate discussing the optimal timing for Lutetium-177 (Pluvicto) therapy in advanced prostate cancer. The discussion will focus on the potential advantages of earlier use of the radioligand therapy.

January 2026 — 2 developments

  2. UCLA Health has initiated the Phase 2 ANDROMEDA clinical trial to investigate combined precision radiation and targeted radioactive therapy for recurrent prostate cancer.

    UCLA Health has initiated the Phase 2 ANDROMEDA clinical trial to investigate combined precision radiation and targeted radioactive therapy for recurrent prostate cancer. The study will compare lutetium-177–PSMA-617 and actinium-225–PSMA-617.

November 2025 — 1 developments

  1. A new clinical trial from UCLA Health found that adding PSMA-targeted radioligand therapy before ste…

    A new clinical trial from UCLA Health found that adding PSMA-targeted radioligand therapy before stereotactic body radiotherapy significantly delays disease progression in men with recurrent prostate cancer. This combination therapy showed promising results in improving patient outcomes.

October 2025 — 2 developments

  1. New data from the Phase III PSMAddition study show that Pluvicto™ (lutetium 177 vipivotide tetraxeta…

    New data from the Phase III PSMAddition study show that Pluvicto™ (lutetium 177 vipivotide tetraxetan) in combination with standard of care significantly reduced the risk of progression or death by 28% compared to standard of care alone in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). Novartis also presented promising trial results at ESMO for Pluvicto in mHSPC when combined with standard hormonal therapy, showing an early positive trend in reducing cancer progression.

  2. Novartis announced positive Phase III PSMAddition trial results, showing Pluvicto significantly dela…

    Novartis announced positive Phase III PSMAddition trial results, showing Pluvicto significantly delayed progression to end-stage prostate cancer in metastatic hormone-sensitive prostate cancer (mHSPC).

July 2025 — 1 developments

  1. Novartis' Pluvicto achieved sales of $454 million in Q2 2025, a 22% increase from the previous quart…

    Novartis' Pluvicto achieved sales of $454 million in Q2 2025, a 22% increase from the previous quarter, boosted by an FDA approval in pre-taxane metastatic castration-resistant prostate cancer (mCRPC). In 2025, Novartis also submitted an FDA filing for Pluvicto in PSMA-positive metastatic hormone-sensitive prostate cancer.

March 2025 — 1 developments

  1. The FDA has expanded the indication for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include …

    The FDA has expanded the indication for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone androgen receptor pathway inhibitor (ARPI) therapy. Additionally, data from the PSMAfore clinical trial support the use of 177Lu-PSMA-617 as a new standard treatment for this patient population.

June 2024 — 1 developments

  1. A retrospective study presented at SNMMI 2026 indicated that prior vaccination for prostate cancer-s…

    A retrospective study presented at SNMMI 2026 indicated that prior vaccination for prostate cancer-specific antigens was associated with a significantly higher likelihood of PSA50 response and a reduction in mortality risk when combined with Pluvicto in patients with metastatic castration-resistant prostate cancer (mCRPC). Actinium Pharmaceuticals presented new preclinical data on ATNM-400, demonstrating superior efficacy compared to PSMA-617 radioligands in prostate cancer cells resistant to approved androgen receptor inhibitors. Convergent Therapeutics announced interim data from its Phase 2 CONVERGE-01 study of Ac-225 rosopatamab tetraxetan, showing promising anti-tumor activity, durability, and a favorable tolerability profile in patients previously treated with Lu-177-PSMA.

April 2024 — 1 developments

  1. Novartis announced its plans to file for Pluvicto's approval for earlier use (pre-chemotherapy) in t…

    Novartis announced its plans to file for Pluvicto's approval for earlier use (pre-chemotherapy) in the second half of 2024, based on updated patient survival data from the PSMAfore trial.

October 2023 — 1 developments

  1. Initial data from the Phase III PSMAfore trial were unveiled, demonstrating that Pluvicto met its primary endpoint of radiographic progression-free survival (rPFS).

    Initial data from the Phase III PSMAfore trial were unveiled, demonstrating that Pluvicto met its primary endpoint of radiographic progression-free survival (rPFS).

August 2022 — 1 developments

  1. Pluvicto received its first European approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for use in Great Britain.

    Pluvicto received its first European approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for use in Great Britain.

May 2022 — 1 developments

  1. Novartis announced a temporary, voluntary suspension of production at its radioligand therapy sites in Ivrea, Italy, and Millburn, New Jersey, due to potential quality issues.

    Novartis announced a temporary, voluntary suspension of production at its radioligand therapy sites in Ivrea, Italy, and Millburn, New Jersey, due to potential quality issues. This action led to a temporary suspension of Pluvicto (177Lu-PSMA-617) delivery in the US and a hold on clinical trials for the drug.

March 2021 — 1 developments

  1. The Phase 3 VISION trial, evaluating 177Lu-PSMA-617, met its primary endpoints of overall survival a…

    The Phase 3 VISION trial, evaluating 177Lu-PSMA-617, met its primary endpoints of overall survival and radiographic progression-free survival in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

January 2018 — 1 developments

January 2014 — 1 developments

  1. First clinical experiences with PSMA-617 in the diagnosis and radioligand therapy of prostate cancer…

    First clinical experiences with PSMA-617 in the diagnosis and radioligand therapy of prostate cancer were obtained, and the compound was subsequently licensed to ABX advanced biochemical compounds GmbH.

January 2012 — 1 developments

  1. The development of PSMA-617, the active compound in Pluvicto, began, building on earlier research into urea-based PSMA inhibitors from 2005.

    The development of PSMA-617, the active compound in Pluvicto, began, building on earlier research into urea-based PSMA inhibitors from 2005.